US 12,465,579 B2
Compositions and methods for treating homocystinuria and other conditions
Kenneth N. Maclean, Lakewood, CO (US); Johan Van Hove, Castle Rock, CO (US); Hua Jiang, Centennial, CO (US); and Michael A. Swanson, Denver, CO (US)
Assigned to The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, Denver, CO (US)
Filed on Oct. 8, 2021, as Appl. No. 17/497,539.
Application 17/497,539 is a continuation of application No. PCT/US2020/027721, filed on Apr. 10, 2020.
Claims priority of provisional application 62/832,036, filed on Apr. 10, 2019.
Prior Publication US 2022/0096408 A1, Mar. 31, 2022
Int. Cl. A61K 31/19 (2006.01); A61K 31/145 (2006.01); A61K 31/198 (2006.01); A61K 31/205 (2006.01); A61K 31/4172 (2006.01); A61K 33/30 (2006.01); A61K 33/34 (2006.01); A61P 13/02 (2006.01)
CPC A61K 31/19 (2013.01) [A61K 31/145 (2013.01); A61K 31/198 (2013.01); A61K 31/205 (2013.01); A61K 31/4172 (2013.01); A61K 33/30 (2013.01); A61K 33/34 (2013.01); A61P 13/02 (2018.01)] 29 Claims
OG exemplary drawing
 
1. A pharmaceutical composition for administration to a subject, the composition comprising:
one or more of formate, formate salt, formate ester, diformylglycerol or derivative thereof; diformylglycerol-glucose or derivative thereof, triformyl glycerol or derivative thereof; diformylglycerophosphocholine or derivative thereof, diformylglycerophosphoethanolamine; or derivative thereof, and a pharmaceutically acceptable excipient; and trimethylglycine or derivative thereof further comprising zinc, zinc conjugate or zinc delivery agent or combinations thereof.